- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07628959
Innovative Sleep Quality Analysis Software Compared With Polysomnography (LUNA)
Pilot Study of Innovative Sleep Quality Analysis Software Compared With Polysomnography
To diagnose sleep disorders, practitioners primarily use polysomnography (PSG), a precise but costly, cumbersome method that is limited to a single observation. This does not allow for longitudinal monitoring of sleep habits in real-world conditions. An alternative is offered with the C. Santé software receiving information from sensors installed on medical bed. This software analyzes cardiorespiratory parameters and sleep phases without disturbing the patient, enabling continuous and comfortable monitoring. A preliminary study aims to validate the reliability of the C. Santé software analysis, by comparing it to the PSG analysis, considered the gold standard.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Bruno STIMMESSE, MD
- Telefonnummer: +33 (0)4 82 77 48 58
- E-post: bstimmesse@mutualite-loire.com
Studer Kontakt Backup
- Navn: Clara PFENNINGER, CDP
- Telefonnummer: +33 (0)4 77 12 08 26
- E-post: clara.pfenninger@chu-st-etienne.fr
Studiesteder
-
-
-
Saint-Etienne, Frankrike, 42000
- Clinique Mutualiste
-
Hovedetterforsker:
- Bruno STIMMESSE, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adult patients aged over 18 years.
- Patients affiliated with or beneficiaries of a social security system.
- Patients capable of completing all aspects of the study.
- Patients who have signed informed consent for participation in the study
Exclusion Criteria:
- pregnancy
- Patients suffering from an acute bacterial, fungal, or viral infection.
- Patients unable to tolerate the placement of the PSG.
- Patients with psychiatric disorders incompatible with the constraints associated with the need to spend two nights at the clinic.
- restless legs syndrome
- Presence of a cardiac pacemaker.
- Cardiac arrhythmia problems (e.g., complete arrhythmia).
- Known and treated sleep disorders (e.g., sleep apnea syndrome) or uncontrolled chronic insomnia.
- Diagnosed dementia.
- Simultaneous participation in other research studies.
- Use of medications that could alter sleepiness, including:
- Sedative-hypnotics.
- Neuroleptics.
- Antidepressants.
- Anxiolytics.
- H1 antihistamines.
- Antiepileptics.
- Opiates and opioid analgesics.
- Patients under legal guardianship or curatorship.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Diagnostisk
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Polysomnography
The patients will spend two consecutive nights on the bed equipped with C. Santé software which is also equipped with traditional polysomnography. |
Patients visit the Sleep Unit at the Clinique Mutualiste for sleep disorders. During their consultation with the doctor, a polysomnography scheduled over two consecutive nights is proposed (this applies to any diagnosis of sleep disorders). At that time, they are also invited to participate in the study. After receiving information about the study and signing the consent form, the patient returns for their two consecutive nights equipped with PSG, which they spend on the bed equipped with sensors transmitting information to C. Santé software. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The agreement in sleep efficiency measurement performed C. Santé software compared to polysomnography (PSG).
Tidsramme: "Up to 3 months after inclusion
|
The study's objective will be met if the sleep efficiency measured by PSG and that calculated from C. Santé software differ by no more than 10%. This means the device will be considered effective if there is at least 90% agreement between PSG and the C. Santé software. |
"Up to 3 months after inclusion
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Accuracy of RR interval measurement
Tidsramme: Up to 3 months after inclusion
|
Determined from the ECG trace of the PSG compared to the C. Santé software |
Up to 3 months after inclusion
|
|
Accuracy of sleep phase duration measurement
Tidsramme: Up to 3 months after inclusion
|
Comparing PSG-calculated durations for sleep stages (N1: light slowwave sleep, N2: intermediate slow-wave sleep, N3: deep slow-wave sleep, REM: rapid eye movement sleep) to the C. Santé software calculation for slow-wave sleep (N) and REM. |
Up to 3 months after inclusion
|
|
Accuracy of respiratory rate measurement
Tidsramme: Up to 3 months after inclusion
|
Comparing C. Santé software measurements to nasal cannula measurements from PSG (analyzed in 30-second intervals) |
Up to 3 months after inclusion
|
|
Accuracy in positional data
Tidsramme: Up to 3 months after inclusion
|
Comparing the time spent lying on the back or side and the number of position changes as calculated by PSG (via a thoracic accelerometer) and by C. Santé software. |
Up to 3 months after inclusion
|
|
Differences in measurements across two consecutive nights
Tidsramme: Up to 3 months after inclusion
|
Differences in measurements across two consecutive nights |
Up to 3 months after inclusion
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Studiestol: Frédéric ROCHE, MD PhD, CHU de Saint-Etienne
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 25CH123
- ANSM (Annen identifikator: 2026-A00074-47)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .